NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Berry Petroleum (BRY) downgraded at Wunderlich from Buy to Hold, Wunderlich said. $40 price target. Company is seeing slower production growth.
CBOE (CBOE) upgraded at KBW from Underperform to Market Perform, Keefe, Bruyette & Woods said. $30 price target. Volatility complex is growing and the company may soon pay a special dividend.Charter Communications (CHTR) rated new Hold at Deutsche. $83 price target. Company faces numerous operational challenges. Eldorado Gold (EGO - Get Report) rated new Overweight at Morgan Stanley. $19 price target. Company can deliver industry-leading growth over the next several years. Exelon (EXC) downgraded at Jefferies from Buy to Hold, Jefferies said. $34 price target. Company is seeing lower prices and may have to cut its dividend. Fluor (FLR) downgraded at Baird from Outperform to Neutral, Robert Baird said. $62 price target. Backlog is likely to trend lower. First Solar (FSLR - Get Report) downgraded at Cantor from Buy to Hold, Cantor Fitzgerald said. Valuation call, based on a $23 price target. Guess (GES) downgraded at Jefferies Buy to Hold, Jefferies said. $25 price target. Company continues to lose managers and lacks near-term catalysts. Iconix (ICON) upgraded at Benchmark from Hold to Buy, Benchmark said. $23 price target. Company is carrying a lot of momentum into the new year and buying back stock. Lifepoint Hospitals (LPNT) downgraded at Cantor from Buy to Hold, Cantor Fitzgerald said. $35 price target. Company has relatively weak earnings leverage. Las Vegas Sands (LVS) downgraded at Cantor from Buy to Hold, Cantor Fitzgerald said. $46 price target. Company is seeing slower growth in Singapore. Mednax (MD) upgraded at Deutsche from Sell to Hold, Deutsche Bank said. $76 price target. Company is posting higher volumes and margins. Pioneer Natural (PXD) downgraded at Canaccord from Hold, Canaccord Genuity said. Valuation call, based on a $110 price target. Rockwell Automation (ROK) upgraded at JP Morgan from Neutral to Overweight, JP Morgan said. $91 price target. Expect a catch up of pent-up demand to cause growth to re-accelerate in the coming quarters.